Cardiovascular disease (CVD) is the leading cause of death in people with diabetes, making assessment, prevention and management of CVD risk a vital part of diabetes care.1 Dr Gary Deed (GP), Dr Tom Dover (endocrinologist) and Michelle Robins (CDE and nurse practitioner) consider the different risk assessment tools available, interventions to manage CVD risk and practical tips on approaching the multi-morbidity nature of type 2 diabetes and the application of patient-centred care. This podcast is intended for healthcare professionals only and should not viewed by anyone but the intended recipient. The views and opinions expressed are those of the presenters and not necessarily those of Sanofi. References: 1. The Royal Australian College of General Practitioners. Management of type 2 diabetes: A handbook for general practice. East Melbourne, Vic: RACGP, 2020. 2. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J. and Broedl, U.C., 2015. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), pp.2117-2128.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related